Stock Events

Stock Events

Spruce Biosciences 

$67.59
43
+$2.24+3.43% Today

Statistics

Day High
69
Day Low
64.28
52W High
1,777.5
52W Low
7
Volume
13,924
Avg. Volume
39,440
Mkt Cap
72.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-24
-16.07
-8.14
-0.21
Expected EPS
-8.815
Actual EPS
N/A

Financials

-1,079.94%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
9.82MRevenue
-106.07MNet Income

Analyst Ratings

$213.40Average Price Target
The highest estimate is 283.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SPRB. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Crinetics Pharmaceuticals
CRNX
Mkt Cap4.04B
Crinetics Pharmaceuticals focuses on endocrine diseases and disorders, directly competing with Spruce Biosciences' focus on endocrinology and rare diseases.
Neurocrine Biosciences
NBIX
Mkt Cap14.28B
Neurocrine Biosciences is involved in neuroendocrine and endocrine diseases, overlapping with Spruce Biosciences' therapeutic areas.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals works on metabolic disorders, a field that intersects with Spruce Biosciences' focus on hormonal disorders.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in the treatment of cystic fibrosis and other serious diseases, competing for similar resources and investment in the biotech space.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for endocrine-based disorders, competing in the broader biopharmaceuticals market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative treatments, competes in the same biopharma space, targeting similar diseases as Spruce Biosciences.
Ligand Pharmaceuticals
LGND
Mkt Cap3.73B
Ligand Pharmaceuticals offers a business model that includes developing drugs for rare diseases, directly competing with Spruce Biosciences' niche focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, competing in the rare disease market space.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical specializes in enzyme replacement therapies for rare genetic disorders, directly competing in the rare diseases sector.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic medicine and rare diseases market.

About

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Show more...
CEO
Mr. Michael G. Grey
Employees
20
Country
US
ISIN
US85209E2081

Listings

XNAS
US
SPRB
BOATS
BOATS
SPRB.BOATS

0 Comments

Share your thoughts

FAQ

What is Spruce Biosciences stock price today?▼
The current price of SPRB is $67.59 USD — it has increased by +3.43% in the past 24 hours. Watch Spruce Biosciences stock price performance more closely on the chart.
What is Spruce Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Spruce Biosciences stocks are traded under the ticker SPRB.
Is Spruce Biosciences stock price growing?▼
SPRB stock has fallen by -3.91% compared to the previous week, the month change is a +22.38% rise, over the last year Spruce Biosciences has showed a +234.13% increase.
What is Spruce Biosciences market cap?▼
Today Spruce Biosciences has the market capitalization of 72.32M
When is the next Spruce Biosciences earnings date?▼
Spruce Biosciences is going to release the next earnings report on May 13, 2026.
What were Spruce Biosciences earnings last quarter?▼
SPRB earnings for the last quarter are -8.73 USD per share, whereas the estimation was -9.16 USD resulting in a +4.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Spruce Biosciences revenue for the last year?▼
Spruce Biosciences revenue for the last year amounts to 9.82M USD.
What is Spruce Biosciences net income for the last year?▼
SPRB net income for the last year is -106.07M USD.
How many employees does Spruce Biosciences have?▼
As of April 01, 2026, the company has 20 employees.
In which sector is Spruce Biosciences located?▼
Spruce Biosciences operates in the Health Care sector.
When did Spruce Biosciences complete a stock split?▼
The last stock split for Spruce Biosciences was on August 07, 2025 with a ratio of 1:75.
Where is Spruce Biosciences headquartered?▼
Spruce Biosciences is headquartered in South San Francisco, US.